신진호
2018-03-06T00:11:41Z
2018-03-06T00:11:41Z
2013-10
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,2013,62(18), p B49-B49
0735-1097
https://www.sciencedirect.com/science/article/pii/S0735109713042861?via%3Dihub
http://hdl.handle.net/20.500.11754/42765
High platelet reactivity (HPR) is associated with poor prognosis in coronary artery disease. Recently PLATO subgroup analysis showed that ticagrelor is better clinical outcome than the clopidogrel, which was related with low HPR. Also many studies reported that adjunctive cilostazol to dual antiplatelet therapy (DAPT) (so called triple antiplatelet therapy; TAT) is better clinical outcome than DAPT, which was associated with a greater antiplatelet effect at 30 days. Thus, this study was designed to compare the effect of ticagrelor and TAT on platelet reactivity with PRU and ARU values.
This study was composed of total 65 patients underwent the coronary stenting. All patients received a 600-mg loading dose of clopidogrel or a 180-mg loading dose of ticagrelor and concomitant aspirin therapy. After patients underwent coronary stenting, they were nonrandomly assigned to 1 of 4 groups: DAPT group (n=15), clopidogrel of 75 mg daily; ticagrelor group (n=20), ticagrelor of 180 mg daily; TAT group (n=15), adjunctive cilostazol of 100 mg twice daily to clopidogrel of 75 mg daily; and triple switch group (n=15), switch of ticagrelor to TAT since 3rd day. The platelet reactivity was assessed by ARU and PRU values at day 2 and day 7, respectively.
en
ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
Cardiac
Cardiovascular Systems
Cardiology
Comparison of effect that ticagrelor and triple antiplatelet therapy affect platelet reactivity
Article
18
62
10.1016/j.jacc.2013.08.886
49-49
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Choe, Seong-Il
Kim, Soon-Gil
Kim, Jeung-Hyeun
Shin, Jin-Ho
2013011018
S
COLLEGE OF MEDICINE[S]
DEPARTMENT OF MEDICINE
jhs2003